Martijn P. Lolkema

This paper validates MeD-seq for cfDNA methylation profiling in cancer patients, showing distinct pre-surgical methylation patterns compared to healthy donors.

SHARC rapidly identifies somatic genomic structural variations from nanopore sequencing for blood-based cancer monitoring, detecting ten SVs per sample and enabling treatment response tracking in metastatic prostate cancer.

This study identifies mutational footprints of six cancer therapies using whole-genome data from metastatic tumors to assess their contribution to mutation burden and risk of driver mutations.

The paper predicts cancer cell-of-origin from DNA sequences by matching mutational landscapes to chromatin modification patterns in normal tissues.